about
Ellagitannins in Cancer Chemoprevention and TherapyCytotoxic and Antitumor Activity of Sulforaphane: The Role of Reactive Oxygen SpeciesPotential Effects of Pomegranate Polyphenols in Cancer Prevention and TherapyIn vitro antitumor activity of cyanidin-3-O-beta-glucopyranosideMitochondrial pathway mediates the antileukemic effects of Hemidesmus indicus, a promising botanical drugSulforaphane potentiates RNA damage induced by different xenobioticsMicronuclei induction, cell cycle delay and apoptosis as markers of cellular stress caused by ursodeoxycholic acid in human lymphocytes.New in vitro approaches to explore cellular and molecular events related to carcinogenesis.Antileukemic activity of sulforaphane in primary blasts from patients affected by myelo- and lympho-proliferative disorders and in hypoxic conditions.Sulforaphane as a promising molecule for fighting cancer.Alkaline nuclear dispersion assays for the determination of DNA damage at the single cell level.Study of the cytotoxic effects of the new synthetic Isothiocyanate CM9 and its fullerene derivative on human T-leukemia cells.In vitro anti-angiogenic effects of Hemidesmus indicus in hypoxic and normoxic conditions.Role of Oxidative RNA Damage in Chronic-Degenerative Diseases.Isothiocyanates as novel cytotoxic and cytostatic agents: molecular pathway on human transformed and non-transformed cells.Broad targeting of resistance to apoptosis in cancer.Sweet chestnut (Castanea sativa Mill.) bark extract: cardiovascular activity and myocyte protection against oxidative damage.Withania somnifera Induces Cytotoxic and Cytostatic Effects on Human T Leukemia Cells.Chemoprevention of cancer by isothiocyanates and anthocyanins: mechanisms of action and structure-activity relationship.Interaction of the isothiocyanate sulforaphane with drug disposition and metabolism: pharmacological and toxicological implications.Apoptosis induction by sulfur-containing compounds in malignant and nonmalignant human cells.Creatine as an antioxidant.Natural isothiocyanates: genotoxic potential versus chemoprevention.Metabolic and toxicological considerations of botanicals in anticancer therapy.Exploring the effects of isothiocyanates on chemotherapeutic drugs.Natural compounds to overcome cancer chemoresistance: toxicological and clinical issues.Isothiocyanate synthetic analogs: biological activities, structure-activity relationships and synthetic strategies.Analysis of radiation-induced micronuclei by FISH using a combination of painting and centromeric DNA probes.Possible Effects of Dietary Anthocyanins on Diabetes and Insulin Resistance.Creatine Prevents the Structural and Functional Damage to Mitochondria in Myogenic, Oxidatively Stressed C2C12 Cells and Restores Their Differentiation Capacity.Inhibition of Cancer Cell Proliferation and Antiradical Effects of Decoction, Hydroalcoholic Extract, and Principal Constituents of Hemidesmus indicus R. Br.Hemidesmus indicus induces apoptosis as well as differentiation in a human promyelocytic leukemic cell line.Sulforaphane induces DNA single strand breaks in cultured human cells.Apoptosis and modulation of cell cycle control by bile acids in human leukemia T cells.Induction of differentiation in human promyelocytic cells by the isothiocyanate sulforaphane.Combination of doxorubicin and sulforaphane for reversing doxorubicin-resistant phenotype in mouse fibroblasts with p53Ser220 mutation.Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations.In vitro anticancer activity of cyanidin-3-O-beta-glucopyranoside: effects on transformed and non-transformed T lymphocytes.A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug.Cold Atmospheric Plasma Induces Apoptosis and Oxidative Stress Pathway Regulation in T-Lymphoblastoid Leukemia Cells.
P50
Q26748955-B12867AD-4A03-414F-817E-7097E07570BFQ26799560-D2A17139-EF23-42D9-B825-D512B3F349BDQ26800877-FA0040C6-1605-488D-9E2A-33704211579FQ28276993-B2068F30-B638-4211-8EED-393A471CAFB1Q28478861-ED1C3B68-2C04-49C8-BA74-82AD39FA094AQ28482480-F415A1C5-E75A-42F8-A5B2-08FEC3A67309Q33182216-C2709BDE-BEF7-4C9B-B0D1-E08C09482C06Q33855155-80AAB0A4-8172-404C-82C7-36A7BAA82DF7Q33896639-49C6DE80-3D5C-4662-9B14-2422C9BFA876Q34376869-A9E6BD1E-52E9-46C3-8E36-A138093568B4Q35026895-EEEE0A60-8886-47F1-A61F-73D1537038DAQ35131562-1F2548DF-9C3B-4FD8-84F3-81FE037BDC98Q35538430-A7E6BCEC-C2FE-45EB-A218-4D0290D84A76Q35675884-6A35498D-2B4B-43DE-BAB2-020A837B566DQ35864044-BB3AB261-E533-4DFE-A2B9-A77C998FE6CAQ36483749-3335B271-C4F7-48F7-A08D-83DAF1E63BD0Q36692053-156A1475-2882-418D-81AA-CE8295685C17Q36946968-FF650288-D736-4752-9DF3-3F2783145A62Q37090062-8767E660-57B6-46B7-B55F-ED93291A76E1Q37264650-55A72AEC-0654-48AB-ABC1-CFF030D26897Q37377789-5BE531C0-F51A-407A-B39E-46977965C1F0Q37853058-3007045A-B189-4C89-81B9-8290F025A40CQ37969540-798D026F-C347-4ED0-B61D-D2A8EAAEE6D8Q38006050-82DB03B9-0300-4CDE-AF5A-40AACD7F9808Q38148572-135136B3-D20F-4C3C-BD22-D40C1F9374F4Q38262078-E561947B-69C0-4F3D-9124-A843833AFE83Q38265413-EED1E163-7AE3-4EDF-A4CA-B149E40C0BB4Q38505175-D655C7C0-4A46-4952-9C1B-5BDDAA6D0950Q38596244-6729FCA6-B863-418E-BB34-CE199628AB94Q38747479-167D6A76-6A86-44AD-B6BC-F10145AB336AQ38901968-36C31047-CDB2-41DD-A777-ABD7D81E043DQ39179871-69EE443D-0784-419D-B6CF-3B0E2C84B7F9Q39699012-EA2E449C-31FB-47E9-99E2-A7BD8EF5F77BQ39805443-259F3D6F-21A4-4965-BBA9-4139603A82CDQ39963780-86CCAEC8-1E4D-481F-A91A-94635E564CF6Q40150731-2A8665A2-83EC-49C3-BCEF-2F9B9C0198D1Q40255489-A1C82948-6F8B-4AC4-8104-63313BFD9137Q40388945-79A4571D-96AA-49ED-AC03-5F62B0569A75Q40427572-56C01102-AEB3-454C-9CCB-D62F7997B9BDQ41694454-72B91043-AE4E-45E1-90B3-40CFAF7C1F53
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carmela Fimognari
@ast
Carmela Fimognari
@en
Carmela Fimognari
@es
Carmela Fimognari
@nl
Carmela Fimognari
@sl
type
label
Carmela Fimognari
@ast
Carmela Fimognari
@en
Carmela Fimognari
@es
Carmela Fimognari
@nl
Carmela Fimognari
@sl
prefLabel
Carmela Fimognari
@ast
Carmela Fimognari
@en
Carmela Fimognari
@es
Carmela Fimognari
@nl
Carmela Fimognari
@sl
P106
P1153
6701497666
P21
P31
P496
0000-0002-2461-8214